Evidence map›Paper›PMID 30586557›Full record

ArticleThe Journal of allergy and clinical immunology2019

The Consortium for Food Allergy Research (CoFAR): The first generation.

Hugh A Sampson, M Cecilia Berin, Marshall Plaut, Scott H Sicherer, Stacie Jones, A Wesley Burks, Robert Lindblad, Donald Y M Leung, Robert A Wood

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03881696 (Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03881696 phase3completednot on this map

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2025Enrolled471ConditionsPeanut Allergy, Multi-food AllergyArmsOmalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Objective sensitization algorithm validates parental report of food allergy in children.The journal of allergy and clinical immunology. Global · 2025
    Article
  3. Omalizumab Implementation in Practice: Lessons Learned From the OUtMATCH Study.The journal of allergy and clinical immunology. In practice · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Oral Immunotherapy for Children with Cow's Milk Allergy.Pathogens (Basel, Switzerland) · 2021
    Review
  9. Advancing Food Allergy Through Omics Sciences.The journal of allergy and clinical immunology. In practice · 2021
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Hugh A SampsonJaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, New York, NY.
M Cecilia BerinJaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, New York, NY.
Marshall PlautNational Institutes of Health/National Institutes of Allergy and Infectious Diseases, Bethesda, Md.
Scott H SichererJaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, New York, NY.
Stacie JonesDepartment of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Ark.
A Wesley BurksDepartment of Pediatrics, University of North Carolina, Chapel Hill, NC.
Robert LindbladEmmes Corporation, Rockville, Md.
Donald Y M LeungDepartment of Pediatrics, National Jewish Health, Denver, Mass.
Robert A WoodDepartment of Pediatrics at the Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: rwood@jhmi.edu.
Icahn School of Medicine at Mount Sinai · USArkansas Children's Hospital · USEmmes (United States) · USJohns Hopkins Medicine · USNational Institutes of Health · USNational Jewish Health · USUniversity of North Carolina at Chapel Hill · US

Funding

Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II StudyUM2AI130836 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BURKS, A. WESLEY, WILLS-KARP, MARSHA · 2017 to 2023
$62.1M
Mechanistic CoreU19AI066738 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI SAMPSON, HUGH A · 2005 to 2016
$43.6M
NIAID NIH HHS U19 AI066738NIAID NIH HHS UM2 AI130836
6 · The paper itself

Abstract

The Consortium for Food Allergy Research (CoFAR) was established by the National Institute of Allergy and Infectious Diseases in 2005 as a collaborative research program bringing together centers focused on the study of food allergy. CoFAR was charged with developing studies to better understand the pathogenesis and natural history of food allergy, as well as potential approaches to the treatment of food allergy. In its first iteration an observational study of infants with milk and egg allergy was established, and studies of oral immunotherapy for egg allergy and sublingual immunotherapy for peanut allergy were initiated, as was a phase 1 study of a recombinant peanut protein vaccine. CoFAR was renewed in 2010 for an additional 5-year period during which the initial observational study was continued, a study of eosinophilic esophagitis was initiated, and new therapeutic trials were established to study epicutaneous immunotherapy for peanut allergy and to compare the safety and efficacy of egg oral immunotherapy to the ingestion of baked egg for the treatment of egg allergy. The results of these efforts will be reviewed in this rostrum, with a brief look to the future of CoFAR.

Indexed as

AllergensAnimalsClinical Studies as TopicDesensitization, ImmunologicEgg Proteins, DietaryEosinophilic EsophagitisFood HypersensitivityGovernment ProgramsHumansMilk ProteinsNational Institute of Allergy and Infectious Diseases (U.S.)United StatesAllergensEgg Proteins, DietaryMilk Proteinsegg allergyepicutaneous immunotherapyFood allergyimmunotherapyoral immunotherapypeanut allergysublingual immunotherapy

Identifiers

PMID30586557
PMCPMC6368887
OpenAlexW2906191281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.